FDA & the Collapse of Lykos: The Opportunity for Psychedelics

Healthcare & Life Sciences Team Co-Leader Michael Werner will join a webinar hosted by Bonaventure Equity LLC (BVE) sharing insights on the U.S. Food and Drug Administration's (FDA) rejection of Lykos' application for MDMA as a treatment for post-traumatic stress disorder (PTSD). In its decision, the agency cited concerns about the study's design, data integrity and lack of clear evidence that the benefits of MDMA outweigh the risks; however, it did encourage Lykos to continue research, indicating the company's current work does not meet standards for clinical trial approval but could receive a favorable response later if Lykos presents more robust evidence. Since the rejection, the business has laid off 75 percent of its staff, and some in the industry have called the decision a major blow to psychedelics. This webinar will contend the opposite: that the development is a net benefit to the advancement of psychedelic treatments, as shown by increased investor interest in the space.